Comparer des méthodes

	Essai clinique randomisé pragmatique	Étude de phase IV
Domaine	Épidémiologie	Épidémiologie
Famille	Process / pipeline	Process / pipeline
Année d'origine	1967	Formalised 1970s–1990s (ICH E3 guideline 1994)
Auteur d'origine	Daniel Schwartz & Joseph Lellouch	Regulatory agencies and pharmaceutical industry (ICH, FDA, EMA frameworks)
Type	Interventional study design	Post-marketing observational or interventional study
Source fondatrice	Schwartz, D., & Lellouch, J. (1967). Explanatory and pragmatic attitudes in therapeutical trials. Journal of Chronic Diseases, 20(8), 637–648.	International Conference on Harmonisation (ICH). (1994). ICH Harmonised Tripartite Guideline: Structure and Content of Clinical Study Reports E3. ICH Secretariat.
Alias	pragmatic RCT, effectiveness trial, real-world RCT, practical clinical trial	post-marketing surveillance study, post-approval study, Phase 4 study, PMS study
Apparentées	6	5
Résumé	A pragmatic randomized clinical trial (pragmatic RCT) is an interventional study that tests whether a treatment works under routine clinical conditions, as opposed to the tightly controlled setting of an explanatory trial. It prioritizes broad eligibility, flexible delivery, and patient-relevant outcomes to answer the question 'Does this treatment work in everyday practice?' rather than 'Can this treatment work under ideal circumstances?' The distinction between pragmatic and explanatory trials was formally articulated by Schwartz and Lellouch in 1967 and operationalized by the PRECIS tool in 2009.	A Phase IV study is a post-marketing surveillance study conducted after a drug, device, or intervention has received regulatory approval. Its primary purpose is to monitor long-term safety, detect rare adverse events, assess effectiveness in routine clinical practice, and explore new indications or populations not adequately represented in earlier trials. Phase IV evidence accumulates continuously throughout a product's commercial life.